New agents for colon and breast cancer

The education session, chaired by Dr Yousef Rustum (Roswell Park Cancer Institute, Buffalo, NY, USA), described many of the newer agents being evaluated for the treatment of colorectal cancer, including thymidylate synthase inhibitors, antifolate antimetabolites, dihydrofolate reductase inhibitors, GAR trans-formylase inhibitors, topoisomerase I inhibitors and alkylating agents. The integrated HER-2neu in breast cancer symposium was large and very interesting; it was co-chaired by Dr Nancy Davidson (Johns Hopkins Oncology Center, Baltimore, MD, USA) and Dr Silvana Martino (The Breast Center, Van Nuys, USA). The latest research on HER-2neu was grouped into one session and was followed by a discussion of the abstracts by Dr Edison Liu (National Cancer Institute, Bethesda, MD, USA).